贝伐单抗联合化疗对铂敏感型复发性卵巢癌的近期疗效及安全性研究

发布时间：2018-02-03 21:51

本文关键词： 贝伐单抗联合化疗复发性卵巢癌铂敏感型　出处：《重庆医学》2017年11期 　论文类型：期刊论文

【摘要】：目的观察贝伐单抗(BEV)联合紫杉醇及铂类药物化疗对铂敏感型复发性卵巢癌的临床疗效和安全性。方法 50例确诊为铂敏感型复发性卵巢癌的患者,分为观察组与对照组。观察组采用BEV联合紫杉醇+卡铂/顺铂方案化疗者20例,对照组采用紫杉醇+卡铂/顺铂方案化疗者30例。化疗前均常规使用地塞米松及5-羟色胺3(5-HT3)拮抗剂,予以抗过敏及止吐。采用实体瘤疗效评价标准(RECIST)1.0版和糖类抗原125(CA125)、人附睾上皮分泌蛋白4(HE4)两个指标综合评价疗效,按照美国国家癌症研究院(NCI)的常见毒性标准3.0版对BEV联合紫杉醇及铂类药物化疗的不良反应进行分级。结果观察组近期有效率为60.0%明显高于对照组26.7%,差异有统计学意义(P0.05)。两组患者不良反应均表现为骨髓抑制、消化道症状、周围神经毒性、脱发及肝肾毒性等,差异无统计学意义(P0.05)。但观察组1例发生腹痛,2例发生腹泻;对照组患者无明显腹痛、腹泻症状。结论 BEV联合紫杉醇及铂类药物化疗对铂敏感型复发性卵巢癌的疗效肯定,耐受性较好,是值得推荐的可行的治疗方法。
[Abstract]:Objective to observe the efficacy and safety of bevacizumab (BEV) combined with paclitaxel and platinum in the treatment of platinum-sensitive recurrent ovarian cancer. 20 patients in the observation group were treated with BEV combined with paclitaxel carboplatin / cisplatin regimen. 30 patients in the control group were treated with paclitaxel carboplatin / cisplatin regimen. Dexamethasone and 5-hydroxytryptamine (5-HT _ 3) antagonists were used routinely before chemotherapy. The criteria for evaluating the efficacy of solid tumor were RECIST1.0 and carbohydrate antigen 125 CA125). Human epididymal epithelial secretory protein 4 (HE4) was used to evaluate the curative effect. According to the National Cancer Institute (NCI). The adverse reactions of BEV combined with paclitaxel and platinum drugs chemotherapy were classified in version 3.0. Results the short-term effective rate of the observation group was 60.0% significantly higher than that of the control group 26.7%. The adverse reactions of the two groups were bone marrow depression, digestive tract symptoms, peripheral neurotoxicity, alopecia and hepatorenal toxicity. The difference was not statistically significant (P 0.05), but in the observation group, 1 case had abdominal pain and 2 cases had diarrhea. Conclusion BEV combined with paclitaxel and platinum drug chemotherapy is effective in the treatment of platinum-sensitive recurrent ovarian cancer. It is a recommended and feasible treatment.
【作者单位】：重庆市肿瘤研究所妇瘤科;
【基金】：重庆市卫生和计划生育委员会基金资助项目(2014-2094)
【分类号】：R737.31
【正文快照】： 位,仅次于子宫颈癌,其中75%的患者就诊时已属晚期。国内外的资料显示,长期以来尽管一些新的、有效的化疗药物出现给卵巢癌的治疗带来了一线希望,但其5年生存率并没有多大提高,仍然在30%~40%。英国一项统计数据显示,2003-2007年确诊的卵巢癌患者5年生存率为41%[1]。究其原因,除

【相似文献】